The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial - PubMed
3 hours ago
- #Metformin
- #Ganwei
- #MASLD
- The study investigates the effectiveness of Metformin and Ganwei in treating Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- A 4-arm randomized, placebo-controlled trial was conducted with 64 MASLD patients divided into groups receiving Metformin alone, Ganwei alone, a combination of both, or a placebo for 6 months.
- Ganwei alone showed significant improvements in liver steatosis, as measured by CAP and kPa scores, compared to placebo and other treatment arms.
- The improvement in liver steatosis with Ganwei was notably effective in patients with the T allele at GNMT rs10948059, indicating a genetic influence on treatment efficacy.
- No serious adverse events were reported across all treatment groups, suggesting Ganwei is a safe and potentially effective treatment option for MASLD.
- The study highlights the role of GNMT promoter activity in the therapeutic effects of Ganwei on MASLD.